ABSTRACT
To safely carry out outpatient chemotherapy, it is important that patients participate in their treatment while maintaining their physical condition, and the medical staff have a role in assisting patients in managing themselves. Therefore, we introduced a self-administered chemotherapy treatment diary(hereinafter referred to as a treatment diary). This helped patients in managing themselves and motivated them to participate in their treatment.
Subject(s)
Self-Management , Humans , Medical Records , Medical Staff , OutpatientsABSTRACT
The clinical outcomes, including adverse events, in 40 advanced breast cancer patients treated with eribulin were analyzed to confirm the effectiveness and safety of this treatment. The objective response rate (ORR) in patients was 35.0%. The median overall survival and time to treatment failure (TTF) in these patients was 479 and 63 days, respectively. Cases wherein eribulin was used as early-line treatment experienced significantly longer TTF compared to the cases wherein eribulin was used as late-line treatment; however, there was no difference in this value according to the breast cancer subtype. Moreover, subtype analysis revealed no significant difference in adverse events. We observed no difference in the benefit or tolerability of eribulin treatment among different breast cancer subtypes. However, our results suggest that a significant therapeutic effect can be expected when using eribulin as early-line treatment.
Subject(s)
Breast Neoplasms/drug therapy , Furans/therapeutic use , Ketones/therapeutic use , Breast Neoplasms/pathology , Furans/adverse effects , Humans , Ketones/adverse effects , Middle Aged , Neoplasm Staging , Treatment OutcomeABSTRACT
The patient was a 40-year-old woman who was aware of a tumor in her left breast that was gradually increasing in size. Ultrasonography revealed a hypoechoic mass with a skin cyst, approximately 3 cm in size, in the C area of the left breast. Core needle biopsy indicated estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and human epidermal growth factor receptor 2 (HER2) -negative squamous cell carcinoma. Overall examination did not indicate distant metastasis. A diagnosis of T4bN2aM0, stage IIIB triple-negative left breast cancer was made. Eribulin was administered at a dose of 1.4 mg/m2. The effect of eribulin was considered to be long-term stable disease( long-term SD). The patient did not experience severe adverse events during treatment. After 24 weeks of eribulin treatment, mastectomy of the left breast with axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that eribulin chemotherapy is useful for the treatment of patients with squamous cell carcinoma of the breast.
Subject(s)
Carcinoma, Squamous Cell/drug therapy , Furans/therapeutic use , Ketones/therapeutic use , Triple Negative Breast Neoplasms/drug therapy , Adult , Biopsy, Large-Core Needle , Carcinoma, Squamous Cell/surgery , Combined Modality Therapy , Humans , Neoplasm Staging , Triple Negative Breast Neoplasms/pathology , Triple Negative Breast Neoplasms/surgeryABSTRACT
A 58-year-old woman observed swelling in her left breast a few weeks prior to presentation. Rigidity in the D area, breast warmth, swelling, and a peau d'orange appearance in the whole left breast was observed. She was diagnosed with inflammatory breast cancer (luminal A type) T4dN2M0, Stage IIIB. The patient underwent primary systemic therapy with 7 courses of FEC. Following FEC treatment, the disease was stable. We subsequently administered 4 courses of bevacizumab plus paclitaxel combination therapy. The patient exhibited a partial response to FEC chemotherapy. Thereafter, a left mastectomy with level II axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Ductal, Breast/drug therapy , Inflammatory Breast Neoplasms/drug therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Bevacizumab , Carcinoma, Ductal, Breast/surgery , Female , Humans , Inflammatory Breast Neoplasms/pathology , Inflammatory Breast Neoplasms/surgery , Mastectomy , Middle Aged , Neoadjuvant Therapy , Paclitaxel/administration & dosageABSTRACT
Two diastereomeric epoxides 4a and 4b corresponding to the C(25)-C(36) fragment of arenicolides A and B were synthesized in a stereoselective manner involving the Pd(0)-catalyzed stereospecific methoxy substitution reaction of epoxy unsaturated ester 6 with B(OMe)(3) as the key step. Comparison of the (1)H NMR spectra of the synthetic compounds with that of arenicolide A revealed that the configuration of the epoxide in arenicolides A and B is 30R and 31R.
Subject(s)
Epoxy Compounds/chemistry , Macrolides/chemistry , Macrolides/chemical synthesis , Stereoisomerism , Substrate SpecificityABSTRACT
Combination chemotherapy of oxaliplatin, fluorouracil/leucovorin (FOLFOX) has reportedly become a standard regimen for colorectal cancer. In this study, we investigated the efficacies and adverse effects of modified FOLFOX6 (m-FOLFOX6) regimen in elderly patients. Thirty-nine patients with colorectal cancer, who received m-FOLFOX6 in our institution, were studied. Ten of the 39 patients, were older than 70 (elderly patients). Efficacies and adverse effects of m-FOLFOX6 were compared between patients over 70 years of age and those younger than 69 (younger patients). In terms of the response rate, there were no differences between the older and younger elderly patients. Moreover, the grade and frequency of adverse events were similar between them. We concluded that m-FOLFOX6 may bring about the same response rate in older and younger elderly patients. Moreover, m-FOLFOX6 may be given safely regardless of patient age.
